INDUSTRY X.O FOR PHARMACEUTICAL MANUFACTURERS

Unlocking the power of digital

Accenture’s global research study of 931 executives looks to understand existing investments in digital technologies, and the challenges to drive value with such investments. More than 85 of the respondents were executives (75% SVP and above) from pharmaceutical companies.

Companies can do more than just change themselves into digital businesses; they can completely reinvent their operating models, production and value chains to create more value with digital. Our research yields a concrete solution: what we call Industry X.O. It’s an action plan for becoming more adept at embracing technological change and profiting from it.

Today’s pharma manufacturers recognize innovation and leading-edge technologies are essential to drive growth, yet their hesitation to transform jeopardizes their ability to future-proof their businesses.

PHARMA MANUFACTURERS RECOGNIZE DIGITAL TECHNOLOGY ADOPTION AND INNOVATION ARE ESSENTIAL TO DRIVE GROWTH

Top 4 strategic priorities over the next 3 years

1. Profitable adoption of new digital technologies
2. Developing innovative products and services
3. Entering new geographic markets
4. More flexible and efficient operations & supply chains

In order to achieve these strategic priorities, pharma executives believe it is important to drive higher operational efficiency and deliver hyper-personalized experiences.
The TOP 5 OBSTACLES that they believe will keep them from leveraging the power of digital technologies to innovate are:

- High cost of digital tech obsolescence: 33%
- Insufficient data security & trust: 32%
- Shortage of digital skills: 28%
- Unable to leverage tech combinations
- Unable to draw on innovative ideas within the ecosystem

And according to more than 90% of executives surveyed, the key to delivering higher operational efficiency and hyper-personalized experiences is innovation with connected and intelligent technologies.

But only 40% of pharma company leaders believe their businesses and operations are ready to innovate with connected and intelligent technologies...and most remain skeptical about readiness in the next 3 years.

More than half of pharma leaders believe they will struggle for survival if they don’t become adept at innovation with digital.
IT'S ALL IN THE COMBINATION PHARMA COMPANIES NEED TO PUSH THROUGH THEIR HESITATION TO REACH THE PAYOFF

Unlock significant financial gains with optimal technology combinations

US$80k (or 42% reduction) By combining five digital technologies, companies could achieve additional average savings of US$80,000 per employee.

US$6.5bn (or 12% increase) A slightly different mix could result in additional average market capitalization of just over US$6 billion for a company.

LEVERAGING THE POWER OF DIGITAL REQUIRES PHARMA COMPANIES TO COMPLETELY REINVENT THEIR BUSINESS —WITH INDUSTRY X.0

Industry X.0 is the digital reinvention of Industry where businesses use advanced digital technologies to transform their core operations, their worker and customer experiences and ultimately their business models. Unlike all previous industrial revolutions, new levels of efficiency are achieved in the core of R&D, engineering, production, manufacturing and business support through integrated systems, processes, sensors and new intelligence. Worker and customer experiences are reimagined and redesigned through personalization and advances such as immersive, augmented and virtual reality. New business models and revenue streams are unlocked by smart, connected products, services and plants that are enabled by new ecosystems.

**INDUSTRY X.0**
Industry 4.0 efficiencies + smart, connected, living and learning products

**INDUSTRY 1.0**
Mechanical production powered by water and steam

**INDUSTRY 2.0**
Mass production based on the division of labor and powered by electrical energy

**INDUSTRY 3.0**
Electronics and IT for automation of production and front/middle/back office

**INDUSTRY 4.0**
Cyber physical production systems
GETTING STARTED: PHARMACEUTICAL COMPANIES MUST BUILD SIX CORE CAPABILITIES

TRANSFORM THE CORE
Digitize and integrate engineering, production, and support for new efficiencies.
Sanofi has invested US$5.5 billion to build out digital plant capabilities. These include autonomous robots (Cobots) that collaborate with human workers, augmented reality for technicians to enable a paperless shop-floor, and a digital twin to simulate future scenarios.
> LEARN MORE

FOCUS ON EXPERIENCES AND OUTCOMES
Create hyper-personalized value to differentiate and lead in the market.
In 2017, Pfizer launched Hemocraft™, a modification of the popular video game Minecraft®, and the HemMobile® Striv® Wearable, a custom wristband, to help people living with hemophilia better approach hemophilia education and activity tracking in the US. The game aims to help younger individuals with hemophilia, 8-16 years of age, learn the importance of integrating treatment into their routine in an educational and fun gaming environment. The wearable helps people living with hemophilia learn about and track different aspects of their disease so that they can have informed conversations with their health care providers.
> LEARN MORE

RE-ARCHITECT THE NEW ECOSYSTEM
Assemble and refresh the right partners to drive new innovation and new capabilities.
Cardinal Health’s Fuse is made up of a diverse team of experts in technology, design and science who identify complex healthcare problems and produce creative business solutions to transform them.
> LEARN MORE

INNOVATE NEW BUSINESS MODELS
Invent new revenue streams for new sources of value.
In late 2016, Novartis partnered with Vodacom to launch Life 2.0, a mobile technology-based healthcare platform in Nigeria. The platform aims to improve the delivery of healthcare for citizens who access public health services. Life 2.0 is designed to improve the availability of chronic or essential medication by monitoring drug stock levels. Novartis has already deployed Life 2.0 in over 250 facilities in the northern state of Kaduna.
> LEARN MORE

BUILD THE WORKFORCE
Source, enable, upskill and protect the next generation of talent.
The corporate training industry is expected to grow at 10 percent CAGR from 2017 through 2020. Its growth is driven by the need to train or reskill increasingly distributed and far-flung workers for a decidedly digital future, making employee training ripe for transformation.
> LEARN MORE

MANAGE THE WISE PIVOTS
Continually balance investment and resource allocation between the core and the new.
In its Geel factory, Sanofi has installed sensors that measure more than 5,000 parameters along the production process and generate over 1 billion data points in every single manufacturing cycle. These are analyzed to monitor and maintain high yield levels and allow for predictive maintenance.
> LEARN MORE

5. Page 33, Redefine Your Company Based on the Company You Keep, Accenture Technology Vision 2018
ABOUT ACCENTURE LIFE SCIENCES

Accenture’s Life Sciences group is committed to helping our clients make a meaningful impact on patients’ lives by combining new science with leading edge technology to revolutionize how medical treatments are discovered, developed and delivered to people around the world. We provide end-to-end business services as well as individual strategy, consulting, digital, technology and operations projects around the globe in all strategic and functional areas—with a strong focus on R&D, Sales & Marketing, Patient Services and the Supply Chain.

We have decades of experiences working with the world’s most successful companies to innovate and improve their performance across the entire Life Sciences value chain. Accenture’s Life Sciences group connects more than 15,000 skilled professionals in over 50 countries who are personally committed to helping our clients achieve their business objectives and deliver better health and economic outcomes.

ABOUT ACCENTURE

Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions—underpinned by the world’s largest delivery network—Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With approximately 442,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com.

ABOUT ACCENTURE RESEARCH

Accenture Research shapes trends and creates data-driven insights about the most pressing issues global organizations face. Combining the power of innovative research techniques with a deep understanding of our clients’ industries, our team of 250 researchers and analysts spans 23 countries and publishes hundreds of reports, articles and points of view every year. Our thought-provoking research—supported by proprietary data and partnerships with leading organizations such as MIT and Singularity—guides our innovations and allows us to transform theories and fresh ideas into real-world solutions for our clients. Visit us at http://www.accenture.com/research

CONNECT WITH US

@AccentureLifSci
linkedin.com/company/accenture_life_sciences
www.accenture.com/lifesciencesblog